Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Active not recruiting × Radiodermatitis × Clear all

Phase

Phase NA 2 Phase 2 1

Status

Completed 7 Unknown 3 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 161 Carcinoma, Non-Small-Cell Lung 133 Prostatic Neoplasms 108 Multiple Myeloma 106 Leukemia, Myeloid, Acute 66 Neoplasms 63 Melanoma 63 Colorectal Neoplasms 62 Squamous Cell Carcinoma of Head and Neck 59 Neoplasm Metastasis 57 Lymphoma 55 Pancreatic Neoplasms 54 Lung Neoplasms 53 Ovarian Neoplasms 48 Sarcoma 42 Recurrence 38 Leukemia, Lymphocytic, Chronic, B-Cell 38 Triple Negative Breast Neoplasms 37 Glioblastoma 37 Lymphoma, Large B-Cell, Diffuse 36 Head and Neck Neoplasms 36 Precursor Cell Lymphoblastic Leukemia-Lymphoma 35 Urinary Bladder Neoplasms 34 Carcinoma, Renal Cell 34 Myelodysplastic Syndromes 32 Lymphoma, Non-Hodgkin 32 Hematologic Neoplasms 32 Brain Neoplasms 30 Stomach Neoplasms 28 Carcinoma, Hepatocellular 28

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07192588 2025-09-25

GuARD

Graegis Pharmaceuticals Ltd

Phase 2 Active not recruiting

Breast Neoplasms, Radiodermatitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡